VectorBuilder and Sartorius Partner to Advance Biopharmaceutical Innovation
Wednesday, November 27, 2024
VectorBuilder has entered into a strategic cooperation agreement with Sartorius.
This collaboration aims to enhance gene vector and mRNA bioprocess solutions, facilitating the development and clinical application of cutting-edge biopharmaceutical projects.
Building on an established partnership, the agreement seeks to expand into areas such as developing advanced downstream processes for cell and gene therapies, optimising platforms for GMP-compliant production of mRNA, plasmids, and viral vectors, and supporting sustainability initiatives.
Additionally, it includes regular exchange programmes and talent training between the two organisations.
VectorBuilder will also play a key role in applications related to new therapeutic modalities. The partnership is expected to deliver innovative solutions that improve the efficiency and quality of biomedical processes, benefiting researchers, pharmaceutical companies, and the wider life sciences sector.
This collaboration underscores both companies’ commitment to advancing cell and gene therapy research and accelerating the development of life-saving treatments.
Source: vectorbuilder.com
